DK2814495T3 - Fremgangsmåde til behandling af tarmsygdomme, der udviser mindst én inflammatorisk komponent - Google Patents

Fremgangsmåde til behandling af tarmsygdomme, der udviser mindst én inflammatorisk komponent Download PDF

Info

Publication number
DK2814495T3
DK2814495T3 DK13704767.6T DK13704767T DK2814495T3 DK 2814495 T3 DK2814495 T3 DK 2814495T3 DK 13704767 T DK13704767 T DK 13704767T DK 2814495 T3 DK2814495 T3 DK 2814495T3
Authority
DK
Denmark
Prior art keywords
procedure
treatment
inflammatory component
intestinal diseases
diseases showing
Prior art date
Application number
DK13704767.6T
Other languages
English (en)
Inventor
Luigi Moro
Gerald Thomas Proehl
Wendell Wierenga
Michael Fangching Huang
Ii Emerson David Ballard
Original Assignee
Cosmo Technologies Ltd
Santarus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd, Santarus Inc filed Critical Cosmo Technologies Ltd
Application granted granted Critical
Publication of DK2814495T3 publication Critical patent/DK2814495T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/606Salicylic acid; Derivatives thereof having amino groups
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK13704767.6T 2012-02-13 2013-02-13 Fremgangsmåde til behandling af tarmsygdomme, der udviser mindst én inflammatorisk komponent DK2814495T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261598308P 2012-02-13 2012-02-13
PCT/EP2013/052838 WO2013120881A1 (en) 2012-02-13 2013-02-13 Method for treating intestinal diseases presenting at least one inflammatory component

Publications (1)

Publication Number Publication Date
DK2814495T3 true DK2814495T3 (da) 2021-08-23

Family

ID=47722264

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13704767.6T DK2814495T3 (da) 2012-02-13 2013-02-13 Fremgangsmåde til behandling af tarmsygdomme, der udviser mindst én inflammatorisk komponent

Country Status (15)

Country Link
US (5) US20130209559A1 (da)
EP (1) EP2814495B1 (da)
JP (2) JP2015506999A (da)
CN (2) CN104220076A (da)
AU (1) AU2013220464A1 (da)
BR (1) BR112014020095A8 (da)
CA (1) CA2864065A1 (da)
DK (1) DK2814495T3 (da)
ES (1) ES2882880T3 (da)
HK (1) HK1204927A1 (da)
IL (1) IL234054A0 (da)
IN (1) IN2014DN06662A (da)
PT (1) PT2814495T (da)
RU (1) RU2649807C2 (da)
WO (1) WO2013120881A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2974864B1 (fr) * 2011-05-04 2016-05-27 Snecma Rotor de turbomachine avec moyen de retenue axiale des aubes
AU2014262139A1 (en) * 2013-05-01 2015-11-26 3 Electric Sheep Pty Ltd Event notification systems and methods
WO2015071812A1 (en) * 2013-11-18 2015-05-21 Wockhardt Limited Solid oral modified-release composition comprising budesonide or salt thereof
US10327034B2 (en) * 2014-03-27 2019-06-18 Tvu Networks Corporation Methods, apparatus and systems for exchange of video content
JP2021502382A (ja) * 2017-11-10 2021-01-28 コスモ・テクノロジーズ・リミテツド 経口リファマイシンsv組成物
CN110585164A (zh) * 2019-10-08 2019-12-20 苏州弘森药业股份有限公司 一种艾司奥美拉唑镁碳酸氢钠胶囊的制作方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2274943A1 (en) * 1998-06-17 1999-12-17 Stephen L. Wolman Compositions for the treatment and prevention of inflammatory diseases of the gastrointestinal tract and methods and uses thereof
DE19849737A1 (de) * 1998-10-28 2000-05-04 Falk Pharma Gmbh Kombinationsmittel zur Behandlung entzündlicher Darmerkrankungen
TR200200562T2 (tr) 1999-06-14 2002-05-21 Cosmo S.P.A Vücutta kontrollü şekilde salgılanabilen ve nahoş tadı önleyebilen ağızdan alınmaya mahsus farmasötik bileşimler
US8895064B2 (en) * 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
WO2004087109A1 (ja) * 2003-03-27 2004-10-14 Hisamitsu Pharmaceutical Co., Inc. 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
US20100305076A1 (en) * 2006-09-13 2010-12-02 Chyon-Hwa Yeh Methods of treatment for ulcerative colitis
KR20100038098A (ko) * 2007-06-13 2010-04-12 제이 프라우다 산화 스트레스와 관련된 질병의 진단 및 치료용 물질 및 방법
EP2298321A1 (en) * 2009-08-26 2011-03-23 Nordic Pharma Novel pharmaceutical compositions for treating IBD

Also Published As

Publication number Publication date
US20140187517A1 (en) 2014-07-03
BR112014020095A2 (da) 2017-06-20
CN110693890A (zh) 2020-01-17
RU2649807C2 (ru) 2018-04-04
US20130209559A1 (en) 2013-08-15
US20200163888A1 (en) 2020-05-28
RU2014137128A (ru) 2016-04-10
US20130225537A1 (en) 2013-08-29
ES2882880T3 (es) 2021-12-03
IL234054A0 (en) 2014-09-30
JP6472063B2 (ja) 2019-02-20
CA2864065A1 (en) 2013-08-22
PT2814495T (pt) 2021-08-19
JP2017210476A (ja) 2017-11-30
HK1204927A1 (en) 2015-12-11
IN2014DN06662A (da) 2015-05-22
EP2814495B1 (en) 2021-07-07
US20150017239A1 (en) 2015-01-15
JP2015506999A (ja) 2015-03-05
CN104220076A (zh) 2014-12-17
AU2013220464A1 (en) 2014-09-04
WO2013120881A1 (en) 2013-08-22
EP2814495A1 (en) 2014-12-24
BR112014020095A8 (pt) 2017-07-11

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
DK3076967T3 (da) Fremgangsmåder til behandling af residuelle symptomer på skizofreni
DK2954051T3 (da) Modificeret kapsid til genoverførsel til behandling af nethinden
DK3030323T3 (da) Kdm1a-inhibitorer til behandlingen af sygdom
DK3329884T3 (da) Implanterbar indretning til behandling af glaukom
DK3495380T3 (da) Glucagon/glp-1-coagonister til behandling af obesitas
DK2983787T3 (da) Fremgangsmåde til behandling af posttraumatisk stresssygdom
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3520805T3 (da) Sammensætninger til behandling af myelofibrose
DK2988743T3 (da) Heterocykliske forbindelser, der kan anvendes til behandling af sygdom
DK2895156T3 (da) Fremgangsmåde til fremstilling af terapeutiske nanopartikler
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK2967049T3 (da) Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
DK2818241T3 (da) Fremgangsmåde til fremstilling af behandlingsapparat udstyret med katalysatorbærende honeycombstruktur
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3102213T3 (da) Farmaceutiske sammensætninger til behandlingen af inflammatoriske lidelser
DK3007726T3 (da) Fremgangsmåder til behandling af en tauopati
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK2872497T4 (da) Chromanyl-derivater til behandling af mitokondriel sygdom
DK3265087T3 (da) Fremgangsmåde til behandling med tradipitant
DK2838907T3 (da) Aminosteroider til behandlingen af en ptp1b-associeret sygdom
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK3021839T3 (da) Sammensætninger for behandling af fibrose
DK2900259T3 (da) Glycosidase-regime til behandling af infektionssygdomme